Olanzapine: A New Antipsychotic Agent with Efficacy in the Management of Schizophrenia

Kando, Judith C.; Shepski, John C.; Satterlee, W.; Patel, Jayendra K.; Reams, S.G.; Green, Alan I.

doi:10.1177/106002809703101110

Cited by 31 publications

(18 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the methodological shortcomings and flaws of retrospective chart analysis, these results are consistent with the findings of several multicentre, randomized, controlled, double-blind studies in indicating that olanzapine is a safe and effective antipsychotic medication (4)(5)(6)(7)11). The present chart review adds evidence that it is well suited for use in a population of elderly individuals with dementia and psychotic complications.…”

Section: Limitationssupporting

confidence: 83%

“…In comparison studies, they have shown superior efficacy in the treatment of certain behavioural symptoms, such as decreased verbal fluency and apathy, and in the treatment of patients refractory to typical antipsychotics (1,2). At the same time, they have been shown to reduce the positive symptoms of psychosis, including those caused by dementia (3), at least as well as conventional neuroleptics (4).…”

mentioning

confidence: 99%

“…Olanzapine is one of the newest of the atypical antipsychotics. It was first released to the public in late 1996 (4). It is a member of the thienobenzodiazepine class of serotonin-dopamine antagonists (5).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Olanzapine Use in the Elderly: A Retrospective Analysis

Solomons

Geiger

2000

Can J Psychiatry

View full text Add to dashboard Cite

show abstract

Section: Limitationssupporting

confidence: 83%

mentioning

confidence: 99%

See 1 more Smart Citation

Olanzapine Use in the Elderly: A Retrospective Analysis

Solomons

Geiger

2000

Can J Psychiatry

View full text Add to dashboard Cite

show abstract

“…In another review, 205 more improvement and less attrition was also found in those treated with olanzapine than in those treated with typical comparators. In a third review, 206 olanzapine was found to be equivalent in effectiveness to typical antipsychotic drugs and produced fewer movement disorders. None of these findings differed substantially from the findings of the Cochrane review.…”

Section: Other Systematic Reviewsmentioning

confidence: 99%

A systematic review of atypical antipsychotic drugs in schizophrenia

Bagnall

Jones

Ginnelly

et al. 2003

Health Technol Assess

151

114

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAA systematic review of atypical antipsychotic drugs in schizophrenia NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.The research reported in this monograph was commissioned by the HTA Programme on behalf of the National Institute for Clinical Excellence (NICE). Technology assessment reports are completed in a limited time to inform the appraisal and guidance development processes managed by NICE. The review brings together evidence on key aspects of the use of the technology concerned. However, appraisals and guidance produced by NICE are informed by a wide range of sources.The research reported in this monograph was funded as project number 00/20/01.The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme, NICE or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for any recommendations made by the authors. Criteria for inclusion in the HTA monograph seriesReports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.Reviews in Health Technology Assessment are termed 'syst...

show abstract

“…Adolescents experience considerable intra-individual variability across time despite stable dosing, which appears somewhat greater in adolescents than adults 85,89. The concentration-to-dose ratio of olanzapine appears generally linear 78. However, adolescents appear to have a higher (~34%) concentration-to-dose ratio than adults even after adjustment for weight 90…”

Section: Olanzapine Pharmacology and Pharmacokineticsmentioning

confidence: 99%

Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients

Maloney¹,

Sikich²

2010

NDT

View full text Add to dashboard Cite

BackgroundSevere and persistent mental illnesses in children and adolescents, such as early- onset schizophrenia spectrum (EOSS) disorders and pediatric bipolar disorder (pedBP), are increasingly recognized. Few treatments have demonstrated efficacy in rigorous clinical trials. Enduring response to current medications appears limited. Recently, olanzapine was approved for the treatment of adolescents with schizophrenia or acute manic/mixed episodes in pedBP.MethodsPubMed searches were conducted for olanzapine combined with pharmacology, schizophrenia, or bipolar disorder. Searches related to schizophrenia and bipolar disorder were limited to children and adolescents. The bibliographies of the retrieved articles were hand-checked for additional relevant studies. The epidemiology, phenomenology, and treatment of EOSS and pedBP, and olanzapine’s pharmacology are reviewed. Studies of olanzapine treatment in youth with EOSS and pedBP are examined.ResultsOlanzapine is efficacious for EOSS and pedBP. However, olanzapine is not more efficacious than risperidone, molindone, or haloperidol in EOSS and is less efficacious than clozapine in treatment-resistant EOSS. No comparative trials have been done in pedBP. Olanzapine is associated with weight gain, dyslipidemia, and transaminase elevations in youth. Extrapyramidal symptoms, neuroleptic malignant syndrome, and blood dyscrasias have also been reported but appear rare.ConclusionsThe authors conclude that olanzapine should be considered a second-line agent in EOSS and pedBP due to its risks for significant weight gain and lipid dysregulation. Awareness of the consistent weight and metabolic changes observed in olanzapine-treated youth focused attention on the potential long-term risks of atypical antipsychotics in youth.

show abstract

Olanzapine: A New Antipsychotic Agent with Efficacy in the Management of Schizophrenia

Cited by 31 publications

References 36 publications

Olanzapine Use in the Elderly: A Retrospective Analysis

Olanzapine Use in the Elderly: A Retrospective Analysis

A systematic review of atypical antipsychotic drugs in schizophrenia

Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients

Contact Info

Product

Resources

About